Receptor oligomerization and beyond: A case study in bone morphogenetic proteins

BMC Biology

Volumn 7, Issue , 2009, Pages 59-

  Heinecke, Kai ^a   Seher, Axel ^b   Schmitz, Werner ^a   Mueller, Thomas D ^c   Sebald, Walter ^a   Nickel, Joachim ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; HETERODIMER; HOMODIMER; MUTANT PROTEIN; 3 ((3 CHOLAMIDOPROPYL)DIMETHYLAMMONIUM) 1 PROPANESULFONATE; 3-((3-CHOLAMIDOPROPYL)DIMETHYLAMMONIUM)-1-PROPANESULFONATE; ACTIVIN; ACTIVIN A; ACTIVIN RECEPTOR; BACTERIAL PROTEIN; CHOLIC ACID DERIVATIVE; DETERGENT; GROWTH DIFFERENTIATION FACTOR 5; HYBRID PROTEIN; IMMOBILIZED PROTEIN; ISOPROTEIN; LIGAND;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; LIGAND BINDING; MOUSE; NONHUMAN; OLIGOMERIZATION; PROTEIN STABILITY; RECEPTOR BINDING; WHOLE CELL; ANIMAL; BIOLOGICAL MODEL; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; GENETIC PROCEDURES; GENETIC TRANSFECTION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; PROTEIN DOMAIN; TUMOR CELL LINE;

MAMMALIA;

ACTIVIN RECEPTORS; ACTIVINS; ANIMALS; BACTERIAL PROTEINS; BINDING SITES; BIOSENSING TECHNIQUES; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHOLIC ACIDS; COS CELLS; DETERGENTS; GROWTH DIFFERENTIATION FACTOR 5; HUMANS; IMMOBILIZED PROTEINS; KINETICS; LIGANDS; MODELS, BIOLOGICAL; MUTANT PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN ISOFORMS; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 70350037984     PISSN: None     EISSN: 17417007     Source Type: Journal    
DOI: 10.1186/1741-7007-7-59     Document Type: Article

References (61)

1. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998, 67:753-791. 10.1146/annurev.biochem.67.1.753, 9759503.
2. Heldin CH, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471. 10.1038/37284, 9393997.
3. Kingsley DM. What do BMPs do in mammals? Clues from the mouse short-ear mutation. Trends Genet 1994, 10:16-21. 10.1016/0168-9525(94)90014-0, 8146910.
4. Zhao GQ. Consequences of knocking out BMP signaling in the mouse. Genesis 2003, 35:43-56. 10.1002/gene.10167, 12481298.
5. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 1996, 10:1580-1594. 10.1101/gad.10.13.1580, 8682290.
6. Reddi AH. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cyt Growth Factor Rev 1997, 8:11-20.
7. Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 1998, 16:247-252. 10.1038/nbt0398-247, 9528003.
8. Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cyt Growth Factor Rev 1998, 9:49-61.
9. Miyazono K, Kusanagi K, Inoue H. Divergence and convergence of TGF-β/BMP signaling. J Cell Physiol 2001, 187:265-276. 10.1002/jcp.1080, 11319750.
10. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J, Wrana JL. Identification of human activin and TGF β type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993, 75:671-680. 10.1016/0092-8674(93)90488-C, 8242742.
11. Franzen P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin CH, Miyazono K. Cloning of a TGF β type I receptor that forms a heteromeric complex with the TGF β type II receptor. Cell 1993, 75:681-692. 10.1016/0092-8674(93)90489-D, 8242743.
12. Nishitoh H, Ichijo H, Kimura M, Matsumoto T, Makishima F, Yamaguchi A, Yamashita H, Enomoto S, Miyazono K. Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J Biol Chem 1996, 271:21345-21352. 10.1074/jbc.271.5.2769, 8702914.
13. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, Heldin CH, Miyazono K. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci USA 1995, 92:7632-7636. 10.1073/pnas.92.17.7632, 41199, 7644468.
14. Babitt JL, Zhang Y, Samad TA, Xia Y, Tang J, Campagna JA, Schneyer AL, Woolf CJ, Lin HY. Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J Biol Chem 2005, 280:29820-29827. 10.1074/jbc.M503511200, 15975920.
15. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massague J, Niehrs C. Silencing of TGF-β signalling by the pseudoreceptor BAMBI. Nature 1999, 401:480-485. 10.1038/46794, 10519551.
16. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996, 237:295-302. 10.1111/j.1432-1033.1996.0295n.x, 8620887.
17. Allendorph GP, Vale WW, Choe S. Structure of the ternary signaling complex of a TGF-β superfamily member. Proc Natl Acad Sci USA 2006, 103:7643-7648. 10.1073/pnas.0602558103, 1456805,1456805, 16672363.
18. Greenwald J, Groppe J, Gray P, Wiater E, Kwiatkowski W, Vale W, Choe S. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell 2003, 11:605-617. 10.1016/S1097-2765(03)00094-7, 12667445.
19. Kirsch T, Sebald W, Dreyer MK. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol 2000, 7:492-496. 10.1038/75903, 10881198.
20. Klages J, Kotzsch A, Coles M, Sebald W, Nickel J, Muller T, Kessler H. The solution structure of BMPR-IA reveals a local disorder-to-order transition upon BMP-2 binding. Biochemistry 2008, 47:11930-11939. 10.1021/bi801059j, 18937504.
21. Kotzsch A, Nickel J, Seher A, Heinecke K, van Geersdaele L, Herrmann T, Sebald W, Mueller TD. Structure analysis of BMP-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome. J Biol Chem 2008, 283:5876-5887. 10.1074/jbc.M706029200, 18160401.
22. Kotzsch A, Nickel J, Seher A, Sebald W, Muller TD. Crystal structure analysis reveals a spring-loaded latch as molecular mechanism for GDF-5-type I receptor specificity. EMBO J 2009, 28:937-947. 10.1038/emboj.2009.37, 19229295.
23. Thompson TB, Woodruff TK, Jardetzky TS. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-β ligand:receptor interactions. EMBO J 2003, 22:1555-1566. 10.1093/emboj/cdg156, 152900, 12660162.
24. Weber D, Kotzsch A, Nickel J, Harth S, Seher A, Mueller U, Sebald W, Mueller TD. A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Struct Biol 2007, 7:6. 10.1186/1472-6807-7-6, 1802081, 17295905.
25. Nickel J, Kotzsch A, Sebald W, Mueller TD. A single residue of GDF-5 defines binding specificity to BMP receptor IB. J Mol Biol 2005, 349:933-947. 10.1016/j.jmb.2005.04.015, 15890363.
26. Allendorph GP, Isaacs MJ, Kawakami Y, Belmonte JC, Choe S. BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors. Biochemistry 2007, 46:12238-12247. 10.1021/bi700907k, 17924656.
27. Greenwald J, Vega ME, Allendorph GP, Fischer WH, Vale W, Choe S. A flexible activin explains the membrane-dependent cooperative assembly of TGF-β family receptors. Mol Cell 2004, 15:485-489. 10.1016/j.molcel.2004.07.011, 15304227.
28. Yin H, Yeh LC, Hinck AP, Lee JC. Characterization of ligand-binding properties of the human BMP type II receptor extracellular domain. J Mol Biol 2008, 378:191-203. 10.1016/j.jmb.2008.02.031, 18342887.
29. Sachse A, Wagner A, Keller M, Wagner O, Wetzel WD, Layher F, Venbrocks RA, Hortschansky P, Pietraszczyk M, Wiederanders B, Hempeld HJ, Bossertd J, Horne J, Schmucke K, Mollenhauer J. Osteointegration of hydroxyapatite-titanium implants coated with nonglycosylated recombinant human bone morphogenetic protein-2 (BMP-2) in aged sheep. Bone 2005, 37:699-710. 10.1016/j.bone.2005.06.011, 16139577.
30. Hatta T, Konishi H, Katoh E, Natsume T, Ueno N, Kobayashi Y, Yamazaki T. Identification of the ligand-binding site of the BMP type IA receptor for BMP-4. Biopolymers 2000, 55:399-406. 10.1002/1097-0282(2000)55:5<399::AID-BIP1014>3.0.CO;2-9, 11241215.
31. Natsume T, Tomita S, Iemura S, Kinto N, Yamaguchi A, Ueno N. Interaction between soluble type I receptor for bone morphogenetic protein and bone morphogenetic protein-4. J Biol Chem 1997, 272:11535-11540. 10.1074/jbc.272.17.11535, 9111068.
32. Kirsch T, Nickel J, Sebald W. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J 2000, 19:3314-3324. 10.1093/emboj/19.13.3314, 313944, 10880444.
33. Keller S, Nickel J, Zhang JL, Sebald W, Mueller TD. Molecular recognition of BMP-2 and BMP receptor IA. Nat Struct Mol Biol 2004, 11:481-488. 10.1038/nsmb756, 15064755.
34. Iwasaki S, Tsuruoka N, Hattori A, Sato M, Tsujimoto M, Kohno M. Distribution and characterization of specific cellular binding proteins for bone morphogenetic protein-2. J Biol Chem 1995, 270:5476-5482. 10.1074/jbc.270.10.5476, 7890664.
35. Paralkar VM, Hammonds RG, Reddi AH. Identification and characterization of cellular binding proteins (receptors) for recombinant human bone morphogenetic protein 2B, an initiator of bone differentiation cascade. Proc Natl Acad Sci USA 1991, 88:3397-3401. 10.1073/pnas.88.8.3397, 51454, 1849655.
36. Namiki M, Akiyama S, Katagiri T, Suzuki A, Ueno N, Yamaji N, Rosen V, Wozney JM, Suda T. A kinase domain-truncated type I receptor blocks bone morphogenetic protein-2-induced signal transduction in C2C12 myoblasts. J Biol Chem 1997, 272:22046-22052. 10.1074/jbc.272.35.22046, 9268344.
37. Chalaux E, Lopez-Rovira T, Rosa JL, Bartrons R, Ventura F. JunB is involved in the inhibition of myogenic differentiation by bone morphogenetic protein-2. J Biol Chem 1998, 273:537-543. 10.1074/jbc.273.1.537, 9417113.
38. Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, Sundan A, Borset M. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004, 23:3024-3032. 10.1038/sj.onc.1207386, 14691444.
39. Saremba S, Nickel J, Seher A, Kotzsch A, Sebald W, Mueller TD. Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand. FEBS J 2008, 275:172-183.
40. Knaus P, Sebald W. Cooperativity of binding epitopes and receptor chains in the BMP/TGFβ superfamily. Biol Chem 2001, 382:1189-1195. 10.1515/BC.2001.149, 11592400.
41. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI, Knaus P. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 2002, 277:5330-5338. 10.1074/jbc.M102750200, 11714695.
42. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Bloch KD, Peterson RT. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008, 4:33-41. 10.1038/nchembio.2007.54, 2727650, 18026094.
43. Gallea S, Lallemand F, Atfi A, Rawadi G, Ramez V, Spinella-Jaegle S, Kawai S, Faucheu C, Huet L, Baron R, Roman-Roman S. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone 2001, 28:491-498. 10.1016/S8756-3282(01)00415-X, 11344048.
44. Nakamura K, Shirai T, Morishita S, Uchida S, Saeki-Miura K, Makishima F. p38 mitogen-activated protein kinase functionally contributes to chondrogenesis induced by growth/differentiation factor-5 in ATDC5 cells. Exp Cell Res 1999, 250:351-363. 10.1006/excr.1999.4535, 10413589.
45. Liu F, Ventura F, Doody J, Massague J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol 1995, 15:3479-3486. 230584, 7791754.
46. Xia Y, Yu PB, Sidis Y, Beppu H, Bloch KD, Schneyer AL, Lin HY. Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4. J Biol Chem 2007, 282:18129-18140. 10.1074/jbc.M701679200, 17472960.
47. Hassel S, Schmitt S, Hartung A, Roth M, Nohe A, Petersen N, Ehrlich M, Henis YI, Sebald W, Knaus P. Initiation of Smad-dependent and Smad-independent signaling via distinct BMP-receptor complexes. J Bone Joint Surg 2003, 85(Suppl 3):44-51.
48. Hartung A, Bitton-Worms K, Rechtman MM, Wenzel V, Boergermann JH, Hassel S, Henis YI, Knaus P. Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling. Mol Cell Biol 2006, 26:7791-7805. 10.1128/MCB.00022-06, 1636853, 16923969.
49. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003, 18:1842-1853. 10.1359/jbmr.2003.18.10.1842, 14584895.
50. Lavery K, Swain P, Falb D, Alaoui-Ismaili MH. BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. J Biol Chem 2008, 283:20948-20958. 10.1074/jbc.M800850200, 18436533.
51. ten Dijke P, Ichijo H, Franzen P, Schulz P, Saras J, Toyoshima H, Heldin CH, Miyazono K. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 1993, 8:2879-2887.
52. ten Dijke P, Yamashita H, Ichijo H, Franzen P, Laiho M, Miyazono K, Heldin CH. Characterization of type I receptors for transforming growth factor-β and activin. Science 1994, 264:101-104. 10.1126/science.8140412, 8140412.
53. Matzuk MM, Bradley A. Cloning of the human activin receptor cDNA reveals high evolutionary conservation. Biochim Biophys Acta 1992, 1130:105-108.
54. Attisano L, Wrana JL, Cheifetz S, Massague J. Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell 1992, 68:97-108. 10.1016/0092-8674(92)90209-U, 1310075.
55. Kirsch T, Nickel J, Sebald W. Isolation of recombinant BMP receptor IA ectodomain and its 2:1 complex with BMP-2. FEBS Lett 2000, 468:215-219. 10.1016/S0014-5793(00)01214-X, 10692589.
56. Hotten G, Neidhardt H, Jacobowsky B, Pohl J. Cloning and expression of recombinant human growth/differentiation factor 5. Biochem Biophys Res Comm 1994, 204:646-652. 10.1006/bbrc.1994.2508, 7980526.
57. Murata M, Onomichi K, Eto Y, Shibai H, Muramatsu M. Expression of erythroid differentiation factor (EDF) in Chinese hamster ovary cells. Biochem Biophys Res Comm 1988, 151:230-235. 10.1016/0006-291X(88)90583-9, 3348775.
58. Shen BJ, Hage T, Sebald W. Global and local determinants for the kinetics of interleukin-4/interleukin-4 receptor α chain interaction. A biosensor study employing recombinant interleukin-4-binding protein. Eur J Biochem 1996, 240:252-261.
59. Zhang JL, Buehner M, Sebald W. Functional epitope of common γ chain for interleukin-4 binding. Eur J Biochem 2002, 269:1490-1499. 10.1046/j.1432-1033.2002.02796.x, 11874464.
60. Frolik CA, Wakefield LM, Smith DM, Sporn MB. Characterization of a membrane receptor for transforming growth factor-β in normal rat kidney fibroblasts. J Biol Chem 1984, 259:10995-11000.
61. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1990, 31:508-511.